Related Experiment Video
Updated: Dec 27, 2025
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
Published on: January 15, 2010
Double triggers, nasal induction of a Parkinson's disease mouse model
Guobin Song1, Guoping Xi1, Yanhua Li1
1Institute of Brain Science, Shanxi Key Laboratory of Inflammatory Neurodegenerative Diseases, Shanxi Datong University, Datong, 037009, China.
Abstract:
Animal models of Parkinson's disease (PD), a chronic and progressive neurodegenerative disease of the central nervous system (CNS), play a key role in investigating the pathogenesis and developing new therapeutic strategies of PD. However, this goal has been limited by certain weaknesses in the available animal models of PD, e.g., induction by either pro-inflammatory or neurotoxic reagents, or they are too time-/effort-consuming. Here, we report a double triggers, nasal induction of a PD mouse model that mimics the clinical, pathological features and pathogenesis of PD by intranasal (i.n.) administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) combined with lipopolysaccharide (LPS). After administration once every three days for 7 consecutive weeks, these mice displayed enhanced motor dysfunction, loss of dopaminergic neurons, α-synuclein accumulation, as well as activation of microglia and astrocytes in the substantia nigra pars compacta compared with mice that were administered MPTP or LPS alone. This study provides a novel and basic research tool for investigating the pathogenesis and therapeutic intervention of PD.
Insights
This study introduces a new mouse model for Parkinson's disease (PD) using intranasal administration of MPTP and LPS. This model effectively mimics PD's clinical and pathological features, offering a valuable research tool.
Area of Science:
- Neuroscience
- Neurodegenerative Diseases
- Animal Models
Background:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting the central nervous system (CNS).
- Current animal models for PD have limitations, including reliance on toxic reagents or being time- and effort-intensive.
- Developing robust and relevant animal models is crucial for understanding PD pathogenesis and testing therapies.
Purpose of the Study:
- To develop a novel, double-triggered nasal induction method for a Parkinson's disease mouse model.
- To create a model that accurately replicates the clinical, pathological, and pathogenetic features of human PD.
- To provide an improved research tool for investigating PD mechanisms and therapeutic interventions.
Main Methods:
- Intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) combined with lipopolysaccharide (LPS) in mice.
- Administration occurred every three days for seven consecutive weeks.
- Comparison of outcomes between the dual-trigger model and models treated with MPTP or LPS alone.
Main Results:
- The double-triggered model exhibited enhanced motor dysfunction compared to single-trigger models.
- Significant loss of dopaminergic neurons was observed in the substantia nigra pars compacta.
- Increased α-synuclein accumulation and activation of microglia and astrocytes were noted.
Conclusions:
- The novel intranasal MPTP + LPS mouse model effectively recapitulates key aspects of Parkinson's disease.
- This model serves as a valuable tool for advancing research into PD pathogenesis and therapeutic strategies.
- The double-trigger approach offers an improved method for creating relevant PD animal models.
